Loading
Investors avoid genuinely new cancer drugs because most fail in mid-stage trials. A public insurance scheme would repay part of the loss when a first-in-class drug fails honestly, making the bet worth taking.
A publicly-backed reinsurance pool that pays a fraction (for example 40%) of documented phase 2 trial costs back to sponsors of qualifying first-in-class oncology programmes when the trial fails on pre-registered efficacy criteria, with a premium paid by participants and conditions on data disclosure (the failure must be published with full data within twelve months). This directly lowers the risk premium that steers capital toward follow-on assets, and produces a public record of negative results as a by-product. Export credit agencies and crop insurance are analogous risk-sharing designs; the biotech-specific precedent is milestone-based grant funding by CPRIT and BARDA.
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product, Incentives reward me-too drugs and marginal gains.
Shares A single oncology trial data trust with mandatory deposit within eighteen months, The valley of death between lab and product.
Shares Milestone prizes for first-in-class mechanisms reaching human proof of concept, Incentives reward me-too drugs and marginal gains.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.